Clinical Research

Risk factors of lung injury and pulmonary hypertension in patients with chronic obstructive pulmonary disease and the predictive value of serum SDF⁃1 and sRAGE

  • Huiqiang WEI ,
  • Liping GUO ,
  • Yankun HOU ,
  • Xiuling HAO ,
  • Haining LI ,
  • Yongna. CHAI
Expand
  • *.Department of Respiratory Medicine,Eastern Campus,the Second Hospital of Hebei Medical University,Shijiazhuang 050060,China

Received date: 2023-07-28

  Online published: 2024-01-10

Abstract

Objective To analyze the risk factors for lung injury and pulmonary arterial hypertension in patients with chronic obstructive pulmonary disease (COPD), and the predictive value of serum SDF-1 and sRAGE for lung injury and pulmonary arterial hypertension. Methods A total of 200 patients with COPD admitted to our hospital from January 2021 to January 2023 were selected as research objects, 23 of whom occurred lung injury and the rest 177 had no lung injury, and 31 developed pulmonary hypertension and the remaining 169 had no pulmonary hypertension. The predictive value of serum SDF-1 and sRAGE for pulmonary injury and pulmonary hypertension was analyzed. Results Multi-factor logistic regression analysis showed that D-D, PCT, CRP, RDW, MPV, PLT, NLR, SDF-1, sRAGE, pulmonary hypertension, arterial blood oxygen partial pressure, FVC and FEV1 were the main factors affecting lung injury in patients with COPD. D-D, PCT, CRP, RDW, MPV, PLT, NLR, SDF-1, sRAGE, arterial partial oxygen pressure, FVC, FEV1 and CT angiographic pulmonary artery volume were the main factors affecting the occurrence of pulmonary hypertension in those patients (P < 0.05). Serum SDF-1 and sRAGE were positively correlated with lung injury and pulmonary hypertension in patients with COPD (P < 0.05). The sensitivity and accuracy of SDF-1 and sRAGE for predicting lung injury and pulmonary hypertension in patients with COPD were higher than those of SDF-1 and SRage alone (P < 0.05). Conclusions Pulmonary injury in patients with COPD is associated with D-D, PCT, CRP, RDW, MPV, PLT, NLR, SDF-1, sRAGE, pulmonary hypertension, arterial blood oxygen partial pressure, FVC, FEV1. The occurrence of pulmonary hypertension is related to D-D, PCT, CRP, RDW, MPV, PLT, NLR, SDF-1, sRAGE, arterial partial pressure of oxygen, FVC, FEV1 and CT angiography of pulmonary artery volume. Combined detection of SDF-1 and sRAGE has a higher predictive value for lung injury and pulmonary hypertension.

Cite this article

Huiqiang WEI , Liping GUO , Yankun HOU , Xiuling HAO , Haining LI , Yongna. CHAI . Risk factors of lung injury and pulmonary hypertension in patients with chronic obstructive pulmonary disease and the predictive value of serum SDF⁃1 and sRAGE[J]. The Journal of Practical Medicine, 2023 , 39(24) : 3214 -3221 . DOI: 10.3969/j.issn.1006-5725.2023.24.012

References

1 GREDIC M, BLANCO I, KOVACS G, et al. Pulmonary hypertension in chronic obstructive pulmonary Disease[J]. Br J Pharmacol, 2021,178(1):132-151.
2 杨发菊,华毛. 稳定期慢性阻塞性肺疾病患者血管内皮功能的研究[J]. 临床肺科杂志, 2023,28(1):30-34.
3 鞠帅,任帅,赵伟伟. 慢性阻塞性肺疾病急性加重患者严重程度的评估及预测[J]. 临床与病理杂志, 2023,43(1):198-204.
4 李娜,方庆娟,李燕,等. 不同剂量糜蛋白酶雾化吸入联合氨溴索对慢性阻塞性肺疾病患者SIRT-1、SDF-1、FABP4水平的影响[J]. 国际检验医学杂志, 2022,43(9):1085-1089.
5 李庆芬,薛峰. 急性加重期慢性阻塞性肺疾病患者T淋巴细胞及FGF7、SFRP5、sRAGE水平观察[J]. 湖南师范大学学报(医学版), 2022,19(3):85-89.
6 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021,44(3):170-205.
7 中华医学会重症医学分会. 急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006)[J]. 中华急诊医学杂志, 2007,16(4):343-349.
8 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021,101(1):11-51.
9 KOVACS G, AVIAN A, BACHMAIER G, et al. Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic Approach[J]. Chest, 2022,162(1):202-212.
10 FAHIMI F, POURRDOWLAT G, BEHZADNIA N, et al. Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease[J]. Clin Respir J, 2022,16(12):802-811.
11 CONDON D F, AGARWAL S, CHAKRABORTY A,et al. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension[J]. Chest, 2022,161(4):1060-1072.
12 郑亮. CT血管造影肺动脉容积测量诊断肺动脉高压的价值分析[J]. 影像诊断与介入放射学, 2022,31(3):199-204.
13 顾家红,杨少玲,赫兰,等. 慢性阻塞性肺疾病急性加重期患者血清D-二聚体水平与肺动脉高压的相关性研究[J]. 广西医科大学学报, 2022,39(11):1755-1760.
14 朱建丰,徐英. 列线图在老年COPD患者发生肺动脉高压风险预测中的应用[J]. 浙江临床医学, 2022,24(6):822-825.
15 刘爱红,朱雪琴,温涛. C反应蛋白、PCT和动脉血气指标对老年COPD患者合并肺动脉高压的评估价值[J]. 中国老年学杂志, 2022,42(18):4435-4438.
16 魏士刚,闫春良,宿海峰,等. Cys-C和RDW在AECOPD及继发性肺动脉高压患者中的变化及其诊断价值[J]. 热带医学杂志, 2023,23(6):815-818,822.
17 周勇,郑玉龙. 慢性阻塞性肺疾病继发肺动脉高压预测因素分析[J]. 中国医师进修杂志, 2022,45(4):339-344.
18 马大文,王宏俊,胡莎莎. NLR、PLR联合MPV预测老年慢性阻塞性肺疾病患者急性加重期近期预后不良的价值[J]. 检验医学, 2022,37(9):850-854.
19 孙澜,马吉芳,崔乃凡. 慢性阻塞性肺疾病并发肺动脉高压患者血清CCL28和SDF-1表达水平及临床意义[J]. 现代检验医学杂志, 2023,38(1):140-146.
20 陈佩,吴朔,徐溪,等. COPD患者血清IL-38、sRAGE、TLR4、ANGPTL4变化及与疾病严重程度、预后的关系分析[J]. 检验医学与临床, 2022,19(21):2967-2971.
Outlines

/